Page number 75

uiring treatment Novo Nordisk ® Distribution of patients and value across treatment classes 100% 80% 60% 40% 20% 0% Insulin 44% 18% 4% 8% 26% Patients GLP-1 SGLT-2i 5% 17% 15% 22% 40% DPP-IV Value Traditional OADs cover: metformin, sulfonylurea, thiazolidinediones. Numbers do not add up to 100% due to rounding

Page number 76

39 Investor presentation First three months of 2021 Diabetes volume growth remains USD 52 billion diabetes market The number of treated patients 1 is expected to grow by 4% annually towards 2026 CAGR: +4% ILLUSTRATIVE The diabetes realise 5% ann 209m 52bn 2020 2026 Other OAD DPP-4i SGLT-2i 2020 GLP-1 1 Internal estimates; 2 Evaluate April 2021 (consensus forecast based on up to 6 external brokers; Insulin+GLP-1 products are includ Note: GLP-1+basal insulin combination sales are included in insulin; Other OAD includes metformin, SU and TZDs. Growth rates are

    ...